Peterlin P, Jullien M. Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies. haematol [Internet]. 2020Sep.10 [cited 2025Feb.1];. Available from: https://haematologica.org/article/view/11927